The article presents the findings of a study conducted by R. Tao which showed the possible use of histone deacetylase (HDAC) inhibitors in expanding regulatory T cells population in vivo. Researchers found that regulatory T cells have higher amounts of HDAC9 than conventional T cells do. According to the study, HDAC inhibitors might complement therapies for tolerance induction and autoimmune diseases.